371-380 of 613 results
Photo finish for Allens Neota UTS Law Tech Challenge
After five long months of planning, preparation and practice, the Allens Neota UTS Law Tech Challenge for Social Justice culminated in an exciting grand final, with two teams jointly winning the ...
Allens advises Westpac on zipMoney investment
Allens has advised Westpac on its $40 million investment in listed Fintech zipMoney. The deal includes a $40 million equity investment, a grant of up to 9.8 million performance options and a ...
Allens helps deliver a healthy hospital outcome
Allens has advised the Plenary Health consortium on the expansion of the existing Casey Hospital through a series of transactions that closed late last week. The expansion will significantly increa ...
Allens advises Public Transport Victoria on myki re-tendering
In one of the largest and most complex government tender processes in Australia, Allens has advised Public Transport Victoria on the competitive tender for the operation of the myki ticketing syste ...
Allens hosts RegTech Association launch as corporate partner
The RegTech Association, a first-of-its-kind industry body designed to promote Australia's growing regulatory technology industry, has launched with Allens as one of its corporate sponsors. Hosted ...
Allens advises Healthe Care on two major acquisitions
Allens has advised leading Australian private hospital operator Healthe Care Australia in relation to the acquisition of ASX-listed Pulse Health Limited and three hospitals in the Illawarra region ...
2018 Law Tech Challenge explores legal tech for social justice
Helping people who are facing homelessness is just one of the projects currently underway as part of the 2018 Allens Neota UTS Law Tech Challenge for Social Justice. The Challenge addresses one of ...
The High Court has its say on penalties
The high court handed down its decision in Paciocco v Australia and New Zealand banking group limited. ...
What's in a (biosimilar) name?
Because biosimilars and their reference biologic medicine are not identical whether compared to each other or even between biosimilars it is important to know which product has been used ...
Protecting investment in biologic medicines - biological medicines, biosimilars and the challenges they pose
This series of articles is directed towards the part of biotech that is pharmaceutical rather than diagnostic or bioengineering technologies and in particular towards biologic medicines ...